TABLE OF CONTENTS. Volume 4 Number 7 September V. Broshtilova, M. Balabanova S. Huang, Y. H. Zhang.1145
|
|
- Jack Nichols
- 5 years ago
- Views:
Transcription
1
2
3 Journal of Cancer Therapy, 2013, 4, Published Online September 2013 in SciRes ( TABLE OF CONTENTS Volume 4 Number 7 September 2013 Cross Skin Reactivity to Tyrosine Kinase Inhibitors in a Patient with Chronic Myelogenous Leukemia V. Broshtilova, M. Balabanova A Case Report of Fever of Unknown Origin (FUO) S. Huang, Y. H. Zhang.1145 Prolonged Radiographic Stabilization of a Metastatic Octreotide Scan-Positive Poorly Differentiated Neuroendocrine Tumor Using Octreotide Acetate Therapy Alone S. Sorscher 1148 Persimmon Leaf Flavonols Enhance the Anti-Cancer Effect of Heavy Ion Radiotherapy on Murine Xenograft Tumors K. Kawakami, H. Nishida, N. Tatewaki, K. Eguchi-Kasai, K. Anzai, T. Eitsuka, T. Konishi., M. Hirayama Primary Melanoma of the Vagina Treated by Imatinib: Case Report K. Oualla, F. El mrabet, H. Elfatemi, S. Arifi, N. Mellas, A. Banani, S. Tizniti, A. Amarti, O. Elmesbahi 1158 Circulating Tumor Cell Cultures as a Predictive Marker during Salvage Therapy of Refractory Merkel Cell Carcinoma with Chemotherapy and Electron Beam Radiation S. Donepudi, S. A. Reisinger, J. R. McGregor, S. Tharkar, S. Samlowski, D. Ostler, S. Shen, W. E. Samlowski 1162 The Role of Everolimus in the Treatment of Breast Cancer J. P. Leone, R. H. Álvarez 1167 The Aryl Hydrocarbon Receptor: A Target for Breast Cancer Therapy J. B. Powell, G. D. Goode, S. E. Eltom 1177 The MMTV-PyVT Transgenic Mouse as a Multistage Model for Mammary Carcinoma and the Efficacy of Antineoplastic Treatment S. Shishido, A. Delahaye, A. Beck, T. A. Nguyen 1187 Work Productivity and Activity Impairment in Colorectal Cancer Patients Treated with Capecitabine G. Malaguarnera, M. Pennisi, G. Grosso, M. Vacante, S. Salomone, F. Drago, M. Malaguarnera, E. Ozyalcin, M. Motta, V. Raciti, M. Malaguarnera Ductal Carcinoma in Situ Treatment Requires a Multidisciplinary Approach C. Constantinou, I. S. Fentiman Treatment in Elderly Glioblastoma Patients: General Reduction of Standard Therapy Should Be Avoided. Prognostic Value of MGMT Is Questionable J. Pichler, I. Hoellmüller, B. Ghanim, S. Spiegl-Kreinecker 1217 Copyright 2013 SciRes. JCT
4 Journal of Cancer Therapy, 2013, 4, Published Online September 2013 in SciRes ( Work Productivity and Activity Impairment in Breast Cancer Patients Treated with Capecitabine M. Vacante, G. Malaguarnera, M. Pennisi, G. Grosso, S. Salomone, F. Drago, E. Ozyalcin, V. Catania, A. Consoli, M. Malaguarnera Sphincter Saving Surgeries for Locally Advanced Low Rectal Cancer after Neoadjuvant Chemoradiation M. A. E. Salem, H. A. Hamza, G. Amira, A. E. Ibrahium, A. A. S. Salem 1228 Combination Therapy of Capecitabine with Cyclophosphamide as a Second-Line Treatment after Failure of Paclitaxel plus Bevacizumab Treatment in a Human Triple Negative Breast Cancer Xenograft Model M. Yanagisawa, K. Yorozu, M. Kurasawa, Y. Moriya, N. Harada Maintenance Chemotherapy in Ovarian Cancer: A Trial-Sequential Analysis A. Messori, V. Fadda, D. Maratea, S. Trippoli 1242 Annonaa muricata Linn Leaf Induce Apoptosis in Cancer Cause Virus O. P. Astirin, A. N. Artanti, M. S. Fitria, E. A. Perwitasari, A. Prayitno 1244 Clinical and Dosimetric Implications of Air Gaps between Bolus and Skin Surface during Radiation Therapy Y. Khan, J. E. Villarreal-Barajas, M. Udowicz, R. Sinha, W. Muhammad, A. N. Abbasi, A. Hussain 1251 Quality of Life in Egyptian Children with Cancer M. Fawzy, M. Saleh, M. El-Wakil, Z. Monir, E. Eltahlawy Controlled Local Hyperthermia and Magnetic Hyperthermia of Surface (Skin) Cancer Diseases Z. Kovziridze, P. Khorava, N. Mitskevich The figure on the front cover is from the article published in Journal of Cancer Therapy, 2013, Vol. 4, No. 7, pp by José Pablo Leone and Ricardo H. Álvarez. Copyright 2013 SciRes. JCT
5 Journal of Cancer Therapy (JCT) Journal Information SUBSCRIPTIONS The Journal of Cancer Therapy (Online at Scientific Research Publishing, is published monthly by Scientific Research Publishing, Inc., USA. Subscription rates: Print: $59 per issue. To subscribe, please contact Journals Subscriptions Department, SERVICES Advertisements Advertisement Sales Department, Reprints (minimum quantity 100 copies) Reprints Co-ordinator, Scientific Research Publishing, Inc., USA. COPYRIGHT Copyright 2013 Scientific Research Publishing, Inc. All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except as described below, without the permission in writing of the Publisher. Copying of articles is not permitted except for personal and internal use, to the extent permitted by national copyright law, or under the terms of a license issued by the national Reproduction Rights Organization. Requests for permission for other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works or for resale, and other enquiries should be addressed to the Publisher. Statements and opinions expressed in the articles and communications are those of the individual contributors and not the statements and opinion of Scientific Research Publishing, Inc. We assumes no responsibility or liability for any damage or injury to persons or property arising out of the use of any materials, instructions, methods or ideas contained herein. We expressly disclaim any implied warranties of merchantability or fitness for a particular purpose. If expert assistance is required, the services of a competent professional person should be sought. PRODUCTION INFORMATION For manuscripts that have been accepted for publication, please contact: jct@scirp.org
6
ISSN: Vol. 1, No. 1, August 2012
Vol. 1, No. 1, August 2012 9 772169 965001 01 ISSN 2169-9658 (Print) ISSN 2169-9674 (Online) Editorial Board Prof. Massimo Cocchi Dr. Emily Piven Haltiwanger Dr. Ivandro Soares Monteiro Dr. Minati Singh
More informationTABLE OF CONTENTS. Volume 1 Number 5 December P. Saariluoma1, A. Oulasvirta 317. F. Bonoti, P. Metallidou 329
Psychology, 2010, 1, 317-393 Published Online December 2010 in SciRes (http://www.scirp.org/journal/psych/) TABLE OF CONTENTS Volume 1 Number 5 December 2010 User Psychology: Re-assessing the Boundaries
More informationTABLE OF CONTENTS. Volume 2 Number 4 October Symptom Cluster Research in Women with Breast Cancer: A Comparison of Three Subgrouping Techniques
Advances in Breast Cancer Research, 2013, 2, 107-169 Published Online October 2013 in SciRes (http://www.scirp.org/journal/abcr/) TABLE OF CONTENTS Volume 2 Number 4 October 2013 Symptom Cluster Research
More informationTABLE OF CONTENTS. Volume 2, Number 11, November 2010
Vol.2, No.11, 1181-1325 (2010) NS TABLE OF CONTENTS Volume 2, Number 11, November 2010 ASTRONOMY Is it plausible to expect a close encounter of the Earth with a yet undiscovered astronomical object in
More informationFood and Nutrition Sciences, 2011, 2, Published Online October 2011 in SciRes ( TABLE OF CONTENTS
9 772157 944001 08 Food and Nutrition Sciences, 2011, 2, 793-907 Published Online October 2011 in SciRes (http://www.scirp.org/journal/fns/) TABLE OF CONTENTS Volume 2 Number 8 October 2011 Determination
More informationTABLE OF CONTENTS. Volume 3 Number 4 December 2013
Advances in Infectious Diseases, 2013, 3, 231-305 Published Online December 2013 in SciRes (http://www.scirp.org/journal/aid/) TABLE OF CONTENTS Volume 3 Number 4 December 2013 Development of New Strategy
More informationTABLE OF CONTENTS. Volume 3 Number 4 November 2013
Open Journal of Rheumatology and Autoimmune Diseases, 2013, 3, 181-269 Published Online November 2013 in SciRes (http://www.scirp.org/journal/ojra/) TABLE OF CONTENTS Volume 3 Number 4 November 2013 Evaluation
More informationVol.3, No.5, (2013) TABLE OF CONTENTS. Volume 3, Number 5, October 2013
Vol.3, No.5, 419-520 (2013) ABC TABLE OF CONTENTS Volume 3, Number 5, October 2013 Serum lipid growth curves for children and adolescents in predicting adult dyslipidemia (data from the Slovak Lipid Community
More informationTABLE OF CONTENTS. Volume 3 Number 10 October Influence of Traditional Inoculum and Fermentation Time on the Organoleptic Quality of Attiéké
9 772157 944001 1 0 Food and Nutrition Sciences, 2012, 3, 1335-1471 Published Online October 2012 in SciRes (http://www.scirp.org/journal/fns/) TABLE OF CONTENTS Volume 3 Number 10 October 2012 Influence
More informationTABLE OF CONTENTS. Volume 4 Number 12 December 2013
Food and Nutrition Sciences, 2013, 4, 1191-1306 Published Online December 2013 in SciRes (http://www.scirp.org/journal/fns/) TABLE OF CONTENTS Volume 4 Number 12 December 2013 Effects of Pressurized Argon
More informationVol.2, No.1, 1-88 (2012) TABLE OF CONTENTS. Volume 2, Number 1, March 2012
9 772160 879000 01 Vol.2, No.1, 1-88 (2012) OJOG TABLE OF CONTENTS Volume 2, Number 1, March 2012 Metformin: A possible drug for treatment of endometrial cancer K. Tsuji, I. Kisu, K. Banno, M. Yanokura,
More informationTABLE OF CONTENTS. Volume 2 Number 6 August 2011
9 772157 944001 06 Food and Nutrition Sciences, 2011, 2, 511-683 Published Online August 2011 in SciRes (http://www.scirp.org/journal/fns/) TABLE OF CONTENTS Volume 2 Number 6 August 2011 Nutritional
More informationTable of Contents. Volume 7 Number 2 May 2018
9 772168 543002 02 International Journal of Medical Physics, Clinical Engineering and Radiation Oncology, 2018, 7, 131-272 http://www.scirp.org/journal/ijmpcero ISSN Online: 2168-5444 ISSN Print: 2168-5436
More informationTABLE OF CONTENTS. Volume 4 Number 9 September R. Kumar, T. Kathiravan, R. Rajamanickam, S. Nadanasabapathi 873
Food and Nutrition Sciences, 2013, 4, 873-997 Published Online September 2013 in SciRes (http://www.scirp.org/journal/fns/) TABLE OF CONTENTS Volume 4 Number 9 September 2013 Institutional Foods Development
More informationTABLE OF CONTENTS. Volume 4 Number 7A July 2013
Food and Nutrition Sciences, 2013, 4, 1-130 Published Online July 2013 in SciRes (http://www.scirp.org/journal/fns/) TABLE OF CONTENTS Volume 4 Number 7A July 2013 Quantification of Antibiotic Residues
More informationTABLE OF CONTENTS. Volume 4 Number 3 March 2013
Food and Nutrition Sciences, 2013, 4, 233-356 Published Online March 2013 in SciRes (http://www.scirp.org/journal/fns/) TABLE OF CONTENTS Volume 4 Number 3 March 2013 Etiology of Diarrhea among Severely
More informationTable of Contents. Volume 4 Number 13 September 2014
Open Journal of Obstetrics and Gynecology, 2014, 4, 733-808 Published Online September 2014 in SciRes. http://www.scirp.org/journal/ojog Table of Contents Volume 4 Number 13 September 2014 Case Series
More informationTable of Contents. Volume 4 Number 6 April Effect of Carbohydrate Intolerance and Gestational Diabetes on Obstetric and Perinatal Outcomes
Open Journal of Obstetrics and Gynecology, 2014, 4, 243-341 Published Online April 2014 in SciRes. http://www.scirp.org/journal/ojog Table of Contents Volume 4 Number 6 April 2014 Effect of Carbohydrate
More informationTable of Contents. Volume 6 Number 4 November Method for Converting Cone-Beam CT Values into Hounsfield Units for Radiation Treatment Planning
9 772168 543002 04 International Journal of Medical Physics, Clinical Engineering and Radiation Oncology, 2017, 6, 361-467 http://www.scirp.org/journal/ijmpcero ISSN Online: 2168-5444 ISSN Print: 2168-5436
More informationTABLE OF CONTENTS. Synergistic Anti-Tumor Effect of Cisplatin When Combined with an Anti-Src Kinase Integrin-Based Peptide
9 772151 193009 03 Journal of Cancer Therapy, 2011, 2, 295-440 Published Online August 2011 in SciRes (http://www.scirp.org/journal/jct/) TABLE OF CONTENTS Volume 2 Number 3 August 2011 Synergistic Anti-Tumor
More informationTABLE OF CONTENTS. Volume 4 Number 1 February 2014
Open Journal of Rheumatology and Autoimmune Diseases, 2014, 4, 1-73 Published Online February 2014 in SciRes (http://www.scirp.org/journal/ojra/) TABLE OF CONTENTS Volume 4 Number 1 February 2014 Two Approaches
More informationTable of Contents. Volume 4 Number 4 August Involvement of Serotonergic System and Magnesium on Anxiolytic Effects of Pomegranate in Male Mice
World Journal of Neuroscience, 2014, 4, 293-393 Published Online August 2014 in SciRes. http://www.scirp.org/journal/wjns Table of Contents Volume 4 Number 4 August 2014 Involvement of Serotonergic System
More informationTable of Contents. Volume 6 Number 13 December S. Byford, E. Weaver A. Oraif
9 772160 879000 1 3 Open Journal of Obstetrics and Gynecology, 2016, 6, 785-887 http://www.scirp.org/journal/ojog ISSN Online: 2160-8806 ISSN Print: 2160-8792 Table of Contents Volume 6 Number 13 December
More informationTable of Contents. Volume 6 Number 11 August Dietary Calcium Intake and Associated Factors among Pregnant Women in Southern Benin in 2014
Food and Nutrition Sciences, 2015, 6, 945-1070 Published Online August 2015 in SciRes. http://www.scirp.org/journal/fns Table of Contents Volume 6 Number 11 August 2015 Dietary Calcium Intake and Associated
More informationTable of Contents. Volume 7 Number 12 November 2017
9 772160 879000 12 Open Journal of Obstetrics and Gynecology, 2017, 7, 1151-1238 http://www.scirp.org/journal/ojog ISSN Online: 2160-8806 ISSN Print: 2160-8792 Table of Contents Volume 7 Number 12 November
More informationVol.3, No.3, (2013) TABLE OF CONTENTS. Volume 3, Number 3, September F. Y. Jiao, X. P. Yan 177
Vol.3, No.3, 177-289 (2013) OJPed TABLE OF CONTENTS Volume 3, Number 3, September 2013 A special and rare case with osteomyelitis: A case report F. Y. Jiao, X. P. Yan 177 Lead poisoning due to appendiceal
More informationTABLE OF CONTENTS. Volume 5 Number 2 January 2014
Food and Nutrition Sciences, 2014, 5, 97-244 Published Online January 2014 in SciRes (http://www.scirp.org/journal/fns/) TABLE OF CONTENTS Volume 5 Number 2 January 2014 Antioxidant and Antimicrobial Activities
More informationTABLE OF CONTENTS. Volume 3 Number 6 December Genetic Background May Confer Susceptibility to PTC in Benign Multinodular Thyroid Disease
9 772151 193009 06 Journal of Cancer Therapy, 2012, 3, 997-1203 Published Online December 2012 in SciRes (http://www.scirp.org/journal/jct/) TABLE OF CONTENTS Volume 3 Number 6 December 2012 Genetic Background
More informationClinical Policy: Pertuzumab (Perjeta) Reference Number: ERX.SPMN.94
Clinical Policy: (Perjeta) Reference Number: ERX.SPMN.94 Effective Date: 07/16 Last Review Date: 06/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationCommissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
More informationClinical Policy: Regorafenib (Stivarga) Reference Number: CP.PHAR.107 Effective Date: 12/12 Last Review Date: 11/16
Clinical Policy: (Stivarga) Reference Number: CP.PHAR.107 Effective Date: 12/12 Last Review Date: 11/16 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationClinical Policy: Cetuximab (Erbitux) Reference Number: ERX.SPA.261 Effective Date:
Clinical Policy: (Erbitux) Reference Number: ERX.SPA.261 Effective Date: 12.01.18 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationThe Clinical Research E-News
Volume 4: ISSUE 6: August 28, 2012 The Clinical Research E-News Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Trials Opened at
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationSPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Imfinzi) Reference Number: CP.PHAR.339 Effective Date: 07.01.17 Last Review Date: 05.18 Line of Business: Medicaid, HIM-Medical Benefit Coding Implications Revision Log See Important
More informationCopyright 2017 by Rochelle Barlow, ASLDoneRight, ASL Rochelle. All rights reserved.
Copyright 2017 by Rochelle Barlow, ASLDoneRight, ASL Rochelle. All rights reserved. You are welcome to print a copy of this document for your personal use. Other than that, no part of this publication
More informationSummary of Research and Writing Activities in Oncology
Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,
More informationREFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - Executive Summary The table below presents the key metrics for Kadcyla for human epidermal growth factor
More informationNational Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007
Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Herceptin) Reference Number: ERX.SPA.42 Effective Date: 07.01.16 Last Review Date: 05/17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lynparza) Reference Number: CP.PHAR.360 Effective Date: 10.03.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this
More informationREFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics of Cyramza for colorectal cancer (CRC) in the eight major pharmaceutical
More informationCURRICULUM VITAE PERSONAL DETAILS: RAHAL, MOHAMED
PERSONAL DETAILS: CURRICULUM VITAE NAME: RAHAL, MOHAMED MARITAL STATUS: ADDRESS: Married, 3 children King Fahad Specialist Hospital Oncology Department PO BOX 14563 DAMMAM 31434 Kingdom of Saudi Arabia
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationWorkout of the Day. For More Plyometric Workouts, Please Visit:
Workout of the Day For More Plyometric Workouts, Please Visit: http://americancoachingacademy.com/plyometrics/ IT IS ILLEGAL TO POST THIS DOCUMENT ONLINE The material enclosed is copyrighted. You do not
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationClinical Policy: Ramucirumab (Cyramza) Reference Number: CP.HNMC.09 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC
Clinical Policy: (Cyramza) Reference Number: CP.HNMC.09 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy
More informationSynribo (Chronic Myeloid Leukemia)
Synribo (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022 GDHC1141DFR / Published May 2013 Executive Summary Synribo (omacetaxine mepesuccinate): Key Metrics in CML Markets 2012 Synribo Sales
More informationStudienverzeichnis Medizinische Onkologie
Studienverzeichnis Medizinische Onkologie Mammakarzinom, Gynäkologie 21/12 24/14 25/14 96/12 PALLAS I I Transdermal CR1447 (4-OH-testosterone) in endocrine responsive-her2 negative and triple negative-androgen
More informationPRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019
MONDAY, JUNE 3, 2019 7:30 AM - 9:15 AM HIGHLIGHTS OF THE DAY 8:00 AM - 9:00 AM S 8:00 AM - 9:15 AM S S 8:00 AM - 11:00 AM S Highlights of the Day Session II Bringing New and Innovative Glioblastoma Treatments
More informationNHS. High dose rate brachytherapy for carcinoma of the cervix. National Institute for Health and Clinical Excellence. Issue date: March 2006
NHS National Institute for Health and Clinical Excellence Issue date: March 2006 High dose rate brachytherapy for carcinoma of Understanding NICE guidance information for people considering the procedure,
More informationResponsible Alcohol Service for Lafourche Parish
Server Responsibility As a Server of alcohol in the state of Louisiana, it is your responsibility to adhere to the local ordinance governing the sale and service of alcohol and tobacco. Ordinances may
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Erbitux) Reference Number: CP.PHAR.317 Effective Date: 02.01.17 Last Review Date: 11.18 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder
More informationAvastin (bevacizumab)
Avastin (bevacizumab) Policy Number: 5.02.502 Last Review: 04/2018 Origination: 03/2017 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Avastin
More informationClinical Policy: Lapatinib (Tykerb) Reference Number: CP.PHAR.79 Effective Date: Last Review Date: 11.17
Clinical Policy: (Tykerb) Reference Number: CP.PHAR.79 Effective Date: 10.01.11 Last Review Date: 11.17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationClinical Policy: Temozolomide (Temodar) Reference Number: ERX.SPA.138 Effective Date:
Clinical Policy: (Temodar) Reference Number: ERX.SPA.138 Effective Date: 03.01.14 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationPosters and Presentations
Posters and Presentations June 2017: American Society of Clinical Oncology (ASCO) Annual - Preliminary Correlative Analysis of PD-L1 expression from the SUNRISE Study. View April 2017: American Association
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Verzenio) Reference Number: CP.PHAR.355 Effective Date: 10.24.17 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this
More informationImaging Cancer Treatment Complications in the Chest
Imaging Cancer Treatment Complications in the Chest Michelle S. Ginsberg, MD Objectives Imaging Cancer Treatment Complications in the Chest To understand the mechanisms of action of different classes of
More informationMolecular Imaging in the Development of Cancer Therapeutics. Johannes Czernin
Molecular Imaging in the Development of Cancer Therapeutics Johannes Czernin Ahmanson Biological Imaging Division University of California Los Angeles Cancer Statistics Cancer Type 5-year Survival Rate
More informationCPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2 neu-positive breast cancer
CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2 neu-positive breast cancer The Harvard community has made this article openly available. Please share how this
More informationNational Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
More informationConquering Carpal Tunnel Syndrome
Conquering Carpal Tunnel Syndrome PainReliefSciences.com 1 Copyright 2016 NutriFrontier Limited All rights reserved Published by Kevin Richardson. No part of this publication may be reproduced, stored
More informationColorectal Cancer Dashboard
Process Risk Assessment Presence or absence of cancer in first-degree blood relatives documented for patients with colorectal cancer Percent of patients with colorectal cancer for whom presence or absence
More informationTable of Contents. Volume 6 Number 11 May Do Functional Problems and Neighborhood Disturbances in and around the Home Trigger Injuries?
Health, 2014, 6, 1085-1332 Published Online May 2014 in SciRes. http://www.scirp.org/journal/health Table of Contents Volume 6 Number 11 May 2014 Do Functional Problems and Neighborhood Disturbances in
More informationREFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Stivarga for colorectal cancer (CRC) in the eight major
More informationREFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Vectibix for colorectal cancer (CRC) in the eight major
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated
More informationClinical Policy: Ramucirumab (Cyramza) Reference Number: CP.PHAR.119
Clinical Policy: (Cyramza) Reference Number: CP.PHAR.119 Effective Date: 05/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationTreatment of gastrointestinal cancer. General considerations International guidelines
Treatment of gastrointestinal cancer General considerations International guidelines Therapeutical options Chemotherapy Moleculary targeted therapy Irradiation Immunotherapy Radiological intervention Oncosurgery
More informationENETS Consensus Guidelines for the Standard of Care in
Neuroendocrinology (DOI:10.1159/000457957) (Accepted, unedited article not yet assigned to an issue) Advanced Release: February 11, 2017 2017 S. Karger AG, Basel www.karger.com/nen Received: December 12,
More informationCOLORECTAL CANCER 44
COLORECTAL CANCER 44 Colorectal Cancer Highlights from the 2009 Annual Meeting of the American Society of Clinical Oncology Edited by Stuart M. Lichtman, MD Memorial Sloan-Kettering Cancer Center Commack,
More informationQUALIFIED CLINICAL DATA REGISTRY (QCDR) 2017 MEASURE SPECIFICATIONS
QOPI5 Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Percentage of adult patients with metastatic solid tumors
More informationTargeted Medicine and Molecular Therapeutics. Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009
Targeted Medicine and Molecular Therapeutics Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009 Approaches to Cancer Prevention Screening and early diagnosis
More informationLinks in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Oregon. Retirement Date N/A
Local Coverage Determination (LCD): Circulating Tumor Cell Marker Assays (L35096) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information
More informationChronic Myeloid Leukemia (CML)
Chronic Myeloid Leukemia (CML) Japan Drug Forecast and Market Analysis to 2022 GDHC1088CFR / Published April 2013 Executive Summary Sales for CML in Japan The Japan CML therapeutics market in the 7MM is
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationOpen Journal of Stomatology
Volume 7, Number 9, September 2017 Scientific Research Publishing Open Journal of Stomatology www.scirp.org/journal/ojst 9 772160 870007 09 ISSN 2160-8709 (Print) ISSN 2160-8717 (Online) Editor-in-Chief
More informationResponsible Alcohol Service for Jefferson Davis Parish
Server Responsibility As a Server of alcohol in the state of Louisiana, it is your responsibility to adhere to the local ordinance governing the sale and service of alcohol and tobacco. Ordinances may
More informationDenominator Criteria (Eligible Cases): Patient encounter during the performance period (CPT): 78300, 78305, 78306, 78315, 78320
Quality ID #147: Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationCADTH RAPID RESPONSE REPORT: REFERENCE LIST Side Effect Free Chemotherapy for the Treatment of Cancer: Clinical Effectiveness
CADTH RAPID RESPONSE REPORT: REFERENCE LIST Side Effect Free Chemotherapy for the Treatment of Cancer: Clinical Effectiveness Service Line: Rapid Response Service Version: 1.0 Publication Date: August
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Stivarga) Reference Number: CP.PHAR.107 Effective Date: 12.01.12 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of
More informationSTATE OF THE ART 4: Combination Immune Therapy-Chemotherapy. Elizabeth M. Jaffee (JHU) James Yang (NCI) Jared Gollob (Duke) John Kirkwood (UPMI)
STATE OF THE ART 4: Combination Immune Therapy-Chemotherapy Elizabeth M. Jaffee (JHU) James Yang (NCI) Jared Gollob (Duke) John Kirkwood (UPMI) Topics for Consideration What are the rules for integrating
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Stivarga) Reference Number: CP.CPA.157 Effective Date: 11.16.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationCLINICAL TRIALS ACC. Jul 2016
CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
More informationNCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and
More informationWASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles
2 3 Mt. Vernon Port Angeles Bremerton Tacoma 5 5 Olympia Everett Edmonds Seattle 90 WASHINGTON 90 Spokane Cheney Pullman Longview 82 Tri-Cities Portland North Central Oregon City 5 84 OREGON Walla Walla
More informationResponsible Alcohol Service for Ascension Parish
Server Responsibility As a Server of alcohol in the state of Louisiana, it is your responsibility to adhere to the local ordinance governing the sale and service of alcohol and tobacco. Ordinances may
More informationCancer Metronomic Therapy Milan, February 26, 2016
Cancer Metronomic Therapy Milan, February 26, 2016 Metronomic Chemotherapy: Evolution and Development of the Concept Robert S. Kerbel, PhD Senior Scientist Sunnybrook Research Institute Professor, Dept.
More informationClinical Policy: Pertuzumab (Perjeta) Reference Number: CP.PHAR.227 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Perjeta) Reference Number: CP.PHAR.227 Effective Date: 06.01.16 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the
More informationResponsible Alcohol Service for St. Martin Parish
Server Responsibility As a Server of alcohol in the state of Louisiana, it is your responsibility to adhere to the local ordinance governing the sale and service of alcohol and tobacco. Ordinances may
More informationBreast Cancer Diagnosis, Treatment and Follow-up
Breast Cancer Diagnosis, Treatment and Follow-up What is breast cancer? Each of the body s organs, including the breast, is made up of many types of cells. Normally, healthy cells grow and divide to produce
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationSami Shousha Editor. Breast Pathology. Problematic Issues
Breast Pathology Editor Breast Pathology Problematic Issues Editor Charing Cross Hospital Imperial College Healthcare NHS Trust & Imperial College London United Kingdom ISBN 978-3-319-28653-2 ISBN 978-3-319-28655-6
More information